Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

C2300000

Clofibrate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

2-(4-Chlorophenoxy)-2-methylpropionic acid ethyl ester, Ethyl 2-(4-chlorophenoxy)-2-methylpropionate, Ethyl 2-(4-chlorophenoxy)isobutyrate

Sign Into View Organizational & Contract Pricing

Select a Size

0.5 ML
$118.00

$118.00

Estimated to ship onApril 19, 2025

Request a Bulk Order
All Photos(1)

Select a Size

Change View
0.5 ML
$118.00

About This Item

Empirical Formula (Hill Notation):
C12H15ClO3
CAS Number:
637-07-0
Molecular Weight:
242.70
Beilstein/REAXYS Number:
1913459
MDL number:
MFCD00000615
UNSPSC Code:
41116107
PubChem Substance ID:
329774991
NACRES:
NA.24

$118.00

Estimated to ship onApril 19, 2025

Request a Bulk Order

grade

pharmaceutical primary standard

API family

clofibrate

manufacturer/tradename

EDQM

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1

InChI

1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3

InChI key

KNHUKKLJHYUCFP-UHFFFAOYSA-N

Gene Information

human ... PPARA(5465)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Clofibrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

pictograms

CorrosionExclamation mark
GHS05,GHS07

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Eye Dam. 1 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

10 - Combustible liquids

wgk_germany

WGK 3

flash_point_f

235.4 °F - closed cup

flash_point_c

113 °C - closed cup

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Maryam Gholitabar et al.
The Cochrane database of systematic reviews, 12, CD009017-CD009017 (2012-12-14)
There are many pathological conditions leading to an elevated unconjugated bilirubin level (hyperbilirubinaemia) in neonates. Currently the standard therapies for unconjugated hyperbilirubinaemia include phototherapy and exchange transfusion. In addition to phototherapy, clofibrate has been studied as a treatment for hyperbilirubinaemia
G Calais et al.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 22(2), 99-103 (1991-10-01)
It is generally accepted that hypoxia is a common occurrence in many experimental and human tumours and that it is a major cause of local failure after radiotherapy. Many attempts have been made over the last years to eliminate this
H M Mehendale
Toxicological sciences : an official journal of the Society of Toxicology, 57(2), 187-190 (2000-09-28)
The article highlighted in this issue is "Peroxisome Proliferator-Activated Receptor Alpha-Null Mice Lack Resistance to Acetaminophen Hepatotoxicity Following Clofibrate Exposure" by Chuan Chen, Gayle E. Hennig, Herbert E. Whiteley, J Christopher Corton, and José E. Manautou (pp. 338-344).
S Oikawa et al.
Nihon rinsho. Japanese journal of clinical medicine, 52(12), 3285-3291 (1994-12-01)
Clofibrate has cholesterol- and triglyceride-lowering effect. They affect on the various points in the metabolic pathway of lipoproteins. They improve VLDL-synthesis in liver and increase the activity of LPL and hepatic TG lipase. As the results, HDL-cholesterol increases and LDL
J Davignon et al.
Advances in experimental medicine and biology, 201, 111-125 (1986-01-01)
Observation of a markedly depressed HDL-cholesterol (5 mg/dL) in a patient with familial hypercholesterolemia (FH) receiving probucol (1 g/day) and clofibrate (2 g/day) prompted a review of all cases treated by this combination at our lipid clinic. Hypoalphalipoproteinemia (HDL-C less
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service